A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors

Miguel Escobara University of Texas Health Science Center, Houston, TX, USACorrespondence[email protected]

Michael Bullanob Takeda Pharmaceuticals USA, Lexington, MA, USA

Ali G. Mokdadb Takeda Pharmaceuticals USA, Lexington, MA, USA

Jorge Caicedob Takeda Pharmaceuticals USA, Lexington, MA, USA

Bob G. Schultzb Takeda Pharmaceuticals USA, Lexington, MA, USA

Qi Fanb Takeda Pharmaceuticals USA, Lexington, MA, USA

Sumit Vermac STATinMED, Ann Arbor, MI, USA

Your download is now in progress and you may close this window